Thanks to a $250,000 grant from the National Multiple Sclerosis Society, Endece Neural, a subsidiary company of Mequon-based drug discovery company Endece LLC, is forging ahead with preclinical research of a drug compound that it believes could revolutionize treatment options for people living with multiple sclerosis (MS).
Read the full story here, in the Oct. 28 issue of BizTimes Milwaukee magazine.
Share new hires, promotions and employee accolades with the region's business leaders.
Up-to-the-minute business news, thoughtful analysis and valuable strategic insights for Milwaukee and Southeastern Wisconsin business leaders.
Copyright © 2024 BizTimes - Milwaukee Business News. All Rights Reserved.
Holiday flash sale!
Limited time offer. New subscribers only.
Subscribe to BizTimes Milwaukee and save 40%
Holiday flash sale! Subscribe to BizTimes and save 40%!
Limited time offer. New subscribers only.
